You are here

Keytruda

GSK stops Keytruda combo trials after ICOS drug falls short

GSK stops Keytruda combo trials after ICOS drug falls short

Fierce Biotech

clinical trials

Flag link:

Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use

Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use

Fierce Pharma

renal cell carcinoma

clinical trials

Flag link:

FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm

FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm

Endpoints

triple negative breast cancer

Flag link:

FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm

FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm

Endpoints

triple negative breast cancer

Flag link:

Merck Scores Latest Label Expansion for Keytruda in Esophageal Carcinomas

Merck Scores Latest Label Expansion for Keytruda in Esophageal Carcinomas

BioSpace

esophageal cancer

Flag link:

Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer

Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer

Endpoints

clinical trials

endometrial cancer

Flag link:

Surface Oncology To Test SRF388 Plus Keytruda Combo In Solid Tumor Settings

Surface Oncology To Test SRF388 Plus Keytruda Combo In Solid Tumor Settings

Benzinga

Surface Oncology

Flag link:

Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?

Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?

Fierce Pharma

small cell lung cancer

Bristol-Myers Squibb

Flag link:

Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?

Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?

Endpoints

non-small cell lung cancer

Flag link:

Did Merck Make a Mistake With a Key FDA Filing?

Did Merck Make a Mistake With a Key FDA Filing?

Motley Fool

triple negative breast cancer

Flag link:

Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer

Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer

BioSpace

renal cell carcinoma

Flag link:

Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med

Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med

Endpoints

advanced kidney cancer

Flag link:

FDA panel admonishes Merck with a gentle — and rare — slapdown for rushing its pitch on an accelerated OK for adjuvant Keytruda in TNBC

FDA panel admonishes Merck with a gentle — and rare — slapdown for rushing its pitch on an accelerated OK for adjuvant Keytruda in TNBC

Endpoints

Flag link:

FDA Action Alert: Adamas, Mallinckrodt and Merck

FDA Action Alert: Adamas, Mallinckrodt and Merck

BioSpace

Adamas Pharmaceuticals

triple negative breast cancer

Flag link:

Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy

Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy

BioSpace

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer

WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer

Fierce Pharma

Bristol-Myers Squibb

Flag link:

The year immuno-oncology could break into perioperative settings

The year immuno-oncology could break into perioperative settings

EP Vantage

immuno-oncology

perioperative breast cancer

Flag link:

GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer

GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer

Fierce Biotech

bintrafusp alfa

Flag link:

Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China

Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China

Fierce Pharma

Bristol-Myers Squibb

PD-1 inhibitors

Flag link:

FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer

FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer

Pharmaceutical Business Review

esophageal cancer

gastroesophageal cancer

Flag link:

Pages